Repurposing of drug candidates for treatment of skin cancer
author
Abstract:
Skin cancers are highly prevalent malignancies that affect millions of people worldwide. These include melanomas and nonmelanoma skin cancers. Melanomas are among the most dangerous cancers, while nonmelanoma skin cancers generally exhibit a more benign clinical pattern; however, they may sometimes be aggressive and metastatic. Melanomas typically appear in body regions exposed to the sun, although they may also appear in areas that do not usually get sun exposure. Thus, their development is multifactorial, comprising endogenous and exogenous risk factors. The management of skin cancer depends on the type; it is usually based on surgery, chemotherapy, immunotherapy, and targeted therapy. In this respect, oncological treatments have demonstrated some progress in the last years; however, current therapies still present various disadvantages such as little cell specificity, recurrent relapses, high toxicity, and increased costs. Furthermore, the pursuit of novel medications is expensive, and the authorization for their clinical utilization may take 10-15 years. Thus, repositioning of drugs previously approved and utilized for other diseases has emerged as an excellent alternative. In this mini-review, we aimed to provide an updated overview of drugs’ repurposing to treat skin cancer and discuss future perspectives.
similar resources
comparison of zoe and vitapex for canal treatment of necrotic primary teeth
چکیده ندارد.
15 صفحه اولDrug Repurposing for Cancer Therapy.
In the mid-1980s, a French company geared its efforts toward developing a synthetic steroid capable of blocking the glucocorticoid receptor in order to potentially treat Cushing’s syndrome. Preclinical studies revealed that the compound developed, termed RU-38486, was indeed a potent antiglucocorticoid agent [1], yet with a caveat: if given to pregnant animals, it terminated pregnancy [2-4]. Th...
full textNew drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing
BACKGROUND Atypical meningiomas are common central nervous system neoplasms with high recurrence rate and poorer prognosis compared to their grade I counterparts. Surgical excision and radiotherapy remains the mainstay therapy but medical treatments are limited. We explore new drug candidates using computational drug repurposing based on the gene expression signature of atypical meningioma tiss...
full textExposing the Molecular Screening Method of Indonesian Natural Products Derivate as Drug Candidates for Cervical Cancer
The menace of cervical cancer has reached an alarming rate. There are more than 450.000cases of cervical cancer yearly, with mortality rate of about 50%. This deadly cancer is causedby human papillomavirus (HPV), mainly subtypes 16 and 18. The pharmaceutical industryhas produced drug for combating the virus, known as SAHA (suberoylanilide hydroxamicacid). It inhibits class II HDAC Homo sapiens ...
full textConstruction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis
Myasthenia gravis (MG) is a rare debilitating autoimmune neuromuscular disorder. Many studies have focused on the mechanism and treatment strategies of MG. However, the exact pathogenesis of MG and effective treatment strategies remain unclear. Recent studies have indicated that microRNAs (miRNAs or miRs) can regulate the pathological pathways of MG, suggesting their potential role in novel tre...
full textRepurposing buspirone for drug addiction treatment.
Bernard Le Foll and Isabelle Boileau 1 Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada 2 Alcohol Research and Treatment Clinic, Addictions Program, CAMH, Toronto, Ontario, Canada 3 Departments of Psychiatry, Pharmacology, Family and Community Medicine and Institute of Medical S...
full textMy Resources
Journal title
volume 13 issue None
pages 107- 118
publication date 2022-08
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023